270 related articles for article (PubMed ID: 30125515)
1. Prostate cancer PET tracers: essentials for the urologist.
Fraum TJ; Ludwig DR; Kim EH; Schroeder P; Hope TA; Ippolito JE
Can J Urol; 2018 Aug; 25(4):9371-9383. PubMed ID: 30125515
[TBL] [Abstract][Full Text] [Related]
2. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
3. Clinical PET Imaging in Prostate Cancer.
Wallitt KL; Khan SR; Dubash S; Tam HH; Khan S; Barwick TD
Radiographics; 2017; 37(5):1512-1536. PubMed ID: 28800286
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
5. Novel imaging in advanced prostate cancer.
Goldberg H; Hamilton RJ
Curr Opin Support Palliat Care; 2017 Sep; 11(3):238-246. PubMed ID: 28590314
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific Membrane Antigen PET in Prostate Cancer.
Lawhn-Heath C; Salavati A; Behr SC; Rowe SP; Calais J; Fendler WP; Eiber M; Emmett L; Hofman MS; Hope TA
Radiology; 2021 May; 299(2):248-260. PubMed ID: 33787338
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
8. The use of PET/CT in prostate cancer.
Li R; Ravizzini GC; Gorin MA; Maurer T; Eiber M; Cooperberg MR; Alemozzaffar M; Tollefson MK; Delacroix SE; Chapin BF
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):4-21. PubMed ID: 29230009
[TBL] [Abstract][Full Text] [Related]
9. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
Sonni I; Baratto L; Iagaru A
PET Clin; 2017 Apr; 12(2):159-171. PubMed ID: 28267450
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Imaging with Novel PET Tracers.
Lindenberg L; Choyke P; Dahut W
Curr Urol Rep; 2016 Mar; 17(3):18. PubMed ID: 26874530
[TBL] [Abstract][Full Text] [Related]
12. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
13. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
Afshar-Oromieh A; Haberkorn U; Eder M; Eisenhut M; Zechmann CM
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1085-6. PubMed ID: 22310854
[No Abstract] [Full Text] [Related]
14. Novel multifunctional
Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
17. PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Vrachimis A; Ferentinos K; Demetriou E; Ioannides C; Zamboglou N
Hell J Nucl Med; 2020; 23(3):339-345. PubMed ID: 33306762
[TBL] [Abstract][Full Text] [Related]
18. Rapidly changing landscape of PET/CT imaging in prostate cancer.
Morigi JJ; Fanti S; Murphy D; Hofman MS
Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
[TBL] [Abstract][Full Text] [Related]
19. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Meyer AR; Joice GA; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Nov; 28(6):493-498. PubMed ID: 30188333
[TBL] [Abstract][Full Text] [Related]
20. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]